iShares Genomics Immunology and Healthcare ETF Rating → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free IDNA Stock Alerts $23.71 +0.01 (+0.04%) (As of 05/31/2024 ET) Add Compare Share Share RatingsStock AnalysisChartHoldingsOwnershipRatingsStock AnalysisChartHoldingsOwnershipRatings iShares Genomics Immunology and Healthcare ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.IDNA Aggregate RatingModerate Buy2.65Holdings in IDNA have an aggregate rating of Moderate Buy based on 363 analyst ratings issued in the past year covering 37 companies (75.8% of the portfolio).IDNA Aggregate Price Target$35.2748.74% UpsideHigh Prediction$51.85Average Prediction$35.27Low Prediction$22.73Holdings in IDNA have an aggregate price target of $35.27 and a range of $22.73 to $51.85 covering 37 companies (75.8% of the portfolio).IDNA Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy11 Buy rating(s)Moderate Buy15 Moderate Buy rating(s)Hold10 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by iShares Genomics Immunology and Healthcare ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 37 IDNA Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.39%MRNAModerna$142.55-5.9%3 of 5 stars2.24$126.46 -11.3%17Insider Selling5.49%RVMDRevolution Medicines$38.33+0.4%4 of 5 stars3.10$43.20 12.7%10Positive News5.18%SRPTSarepta Therapeutics$129.86+4.3%5 of 5 stars2.80$164.00 26.3%15Analyst ForecastHigh Trading Volume4.43%MRKMerck & Co., Inc.$125.54+0.8%4 of 5 stars2.58$131.33 4.6%12Dividend AnnouncementHigh Trading Volume4.28%REGNRegeneron Pharmaceuticals$980.16+1.1%4 of 5 stars2.76$989.36 0.9%21Insider SellingNews CoverageHigh Trading Volume3.76%INCYIncyte$57.79+0.9%5 of 5 stars2.44$73.69 27.5%18Short Interest ↓Positive NewsHigh Trading Volume3.45%BNTXBioNTech$100.60+1.9%2 of 5 stars2.20$111.70 11.0%10Analyst ForecastShort Interest ↓3.32%EXELExelixis$21.69+4.4%5 of 5 stars2.59$26.13 20.4%17Insider BuyingPositive NewsGap Up3.00%GILDGilead Sciences$64.27+0.3%5 of 5 stars2.35$83.69 30.2%17News CoverageGap DownHigh Trading Volume2.85%TWSTTwist Bioscience$41.90+2.6%3 of 5 stars3.00$42.50 1.4%6Positive News2.51%SWTXSpringWorks Therapeutics$41.46-2.7%1 of 5 stars3.00$68.83 66.0%6Analyst Forecast2.43%IOVAIovance Biotherapeutics$8.88-1.3%4 of 5 stars3.00$24.64 177.4%10Analyst ForecastAnalyst Revision2.23%ACLXArcellx$52.00-0.5%3 of 5 stars3.07$78.00 50.0%14Analyst ForecastPositive NewsGap Up2.09%NVAXNovavax$15.03-1.4%4 of 5 stars2.40$17.50 16.4%52.04%BEAMBeam Therapeutics$23.82-1.1%1 of 5 stars2.38$40.18 68.7%13Positive News1.94%GERNGeron$3.55+2.3%4 of 5 stars2.80$6.10 71.8%5Positive News1.79%DVAXDynavax Technologies$11.99+1.4%4 of 5 stars2.75$25.33 111.3%4Analyst DowngradeShort Interest ↑1.73%LGNDLigand Pharmaceuticals$85.05+1.3%5 of 5 stars3.00$116.33 36.8%3Positive News1.50%DCPHDeciphera Pharmaceuticals$25.54+0.0%3 of 5 stars2.30$24.17 -5.4%10Short Interest ↓Positive News1.49%BCRXBioCryst Pharmaceuticals$6.46-1.7%4 of 5 stars3.00$14.00 116.7%7Positive News1.34%BPMCBlueprint Medicines$105.56-0.8%1 of 5 stars2.53$103.94 -1.5%17Positive News1.14%VIRVir Biotechnology$10.27-1.2%2 of 5 stars2.57$33.57 226.9%7Gap Down1.10%FDMT4D Molecular Therapeutics$23.97-2.7%2 of 5 stars3.00$44.22 84.5%101.07%DNAGinkgo Bioworks$0.53-5.4%2 of 5 stars1.67$1.90 259.5%6Short Interest ↓1.04%IBRXImmunityBio$6.42-2.9%0 of 5 stars2.00$6.00 -6.5%1Positive News0.95%RCUSArcus Biosciences$15.07+0.9%2 of 5 stars2.88$41.25 173.7%8News Coverage0.93%ABCLAbCellera Biologics$3.92-3.0%2 of 5 stars3.00$16.17 312.4%7Short Interest ↓0.92%CRSPCRISPR Therapeutics$53.74-0.6%2 of 5 stars2.31$73.46 36.7%16Short Interest ↑Analyst Revision0.91%ARCTArcturus Therapeutics$38.81+0.9%3 of 5 stars3.00$64.86 67.1%7Short Interest ↓Positive News0.82%NRIXNurix Therapeutics$15.75+1.1%2 of 5 stars2.88$21.88 38.9%8Gap UpHigh Trading Volume0.56%EDITEditas Medicine$5.20+0.6%4 of 5 stars2.45$13.27 155.2%11Analyst ForecastAnalyst Revision0.51%OABIOmniAb$4.34-3.1%3 of 5 stars3.00$9.00 107.4%4Insider BuyingPositive News0.48%NTLAIntellia Therapeutics$21.38-3.3%4 of 5 stars2.69$66.77 212.3%13Analyst RevisionPositive News0.33%MGNXMacroGenics$4.09-3.5%5 of 5 stars2.60$12.00 193.4%10News Coverage0.31%XNCRXencor$23.76-0.5%4 of 5 stars2.86$35.43 49.1%7Positive News0.26%CRBUCaribou Biosciences$2.88+1.1%1 of 5 stars2.75$21.50 646.5%4Positive News0.25%QUREuniQure$4.95+5.8%3 of 5 stars2.71$24.75 400.0%7Positive News This page (NYSEARCA:IDNA) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Genomics Immunology and Healthcare ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
